Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2018, Article ID 8283648, 9 pages
Review Article

Cardiac Progenitor Cells in Basic Biology and Regenerative Medicine

1Department of Cell and Molecular Biology, Karolinska Institutet, 171 77 Stockholm, Sweden
2Department of Medicine-Cardiology, Karolinska Institutet, 171 77 Stockholm, Sweden

Correspondence should be addressed to Makoto Sahara; es.ik@arahas.otokam

Received 9 August 2017; Revised 29 November 2017; Accepted 25 December 2017; Published 5 February 2018

Academic Editor: Fatemeh Sharifpanah

Copyright © 2018 Nevin Witman and Makoto Sahara. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Major cardiovascular events including myocardial infarction (MI) continue to dominate morbidity rates in the developed world. Although multiple device therapies and various pharmacological agents have been shown to improve patient care and reduce mortality rates, clinicians and researchers alike still lack a true panacea to regenerate damaged cardiac tissue. Over the previous two to three decades, cardiovascular stem cell therapies have held great promise. Several stem cell-based approaches have now been shown to improve ventricular function and are documented in preclinical animal models as well as phase I and phase II clinical trials. More recently, the cardiac progenitor cell has begun to gain momentum as an ideal candidate for stem cell therapy in heart disease. Here, we will highlight the most recent advances in cardiac stem/progenitor cell biology in regard to both the basics and applied settings.